MiNK Therapeutics, Inc.INKTNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank20
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P20
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2024-44.84%
2023-3.65%
202269.06%
2021270.11%
2020-67.80%
20190.00%